Vaccine company Seqirus reported on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) for AUDENZ to help protect individuals six months of age and older against Pandemic influenza A (H5N1) epidemic, a contagious airborne respiratory disease.
The company said AUDENZ (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic.
Additionally, the novel vaccine AUDENZ combines two leading-edge technologies MF59 adjuvant and cell-based antigen manufacturing, revealed the company.
In December 2015, the US Food and Drug Administration has awarded Fast Track designation for the aH5N1c vaccine for prevention of illness related to pandemic influenza caused by A (H5N1) virus.
According to the company, AUDENZ is designed to be rapidly deployed to help protect the US population and can be stockpiled for first responders in the event of pandemic.
The cell-based vaccine antigen, MF59 adjuvant and formulated prefilled syringes used in the AUDENZ vaccine are all produced in the state-of-the-art Seqirus production facility in Holly Springs, N.C.,which was built and supported through a multi-year public-private partnership with Biomedical Advanced Research and Development Authority (BARDA).
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine